Technical Analysis for ALT - Altimmune, Inc.

Grade Last Price % Change Price Change
D 9.08 -7.91% -0.78
ALT closed down 7.91 percent on Monday, March 18, 2024, on 66 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 26
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Resistance Bearish -7.91%
Stochastic Reached Oversold Weakness -7.91%
Multiple of Ten Bearish Other -7.91%
Wide Bands Range Expansion -7.91%
Oversold Stochastic Weakness -7.91%
Fell Below 20 DMA Bearish -9.43%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 19 hours ago
1.5x Volume Pace about 20 hours ago
Down 5% about 20 hours ago
Down 3% about 20 hours ago
Fell Below Previous Day's Low about 20 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Altimmune, Inc. Description

Altimmune,Inc., formerly Pharmathene, Inc., is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Phosphates Manufacturing Process Vaccines Reversal Manufacturing Processes Nerve Biodefense Choline Biological Warfare Anthrax Chemical Warfare Cholinesterase Anthrax Vaccines Athene

Is ALT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.84
52 Week Low 2.09
Average Volume 6,095,709
200-Day Moving Average 5.37
50-Day Moving Average 10.32
20-Day Moving Average 10.60
10-Day Moving Average 10.37
Average True Range 1.10
RSI (14) 42.53
ADX 15.36
+DI 25.01
-DI 29.39
Chandelier Exit (Long, 3 ATRs) 11.54
Chandelier Exit (Short, 3 ATRs) 11.33
Upper Bollinger Bands 13.55
Lower Bollinger Band 7.65
Percent B (%b) 0.24
BandWidth 55.60
MACD Line -0.02
MACD Signal Line 0.21
MACD Histogram -0.2346
Fundamentals Value
Market Cap 487.86 Million
Num Shares 53.7 Million
EPS -1.54
Price-to-Earnings (P/E) Ratio -5.90
Price-to-Sales 1976.80
Price-to-Book 3.74
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.18
Resistance 3 (R3) 10.28 10.03 9.99
Resistance 2 (R2) 10.03 9.75 9.97 9.93
Resistance 1 (R1) 9.55 9.58 9.43 9.45 9.87
Pivot Point 9.30 9.30 9.23 9.24 9.30
Support 1 (S1) 8.82 9.02 8.70 8.72 8.29
Support 2 (S2) 8.57 8.85 8.51 8.23
Support 3 (S3) 8.09 8.57 8.17
Support 4 (S4) 7.99